분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-03-31 12:41:38 , Hit : 987
 Gilead secures approval in Japan for Sovaldi to treat genotype 2 chronic HCV


PBR Staff Writer
Published 27 March 2015
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Gilead Sciences' Sovaldi (sofosbuvir) for the suppression of viremia in patients with genotype 2 chronic hepatitis C virus (HCV) infection with or without compensated cirrhosis.


Sovaldi, a once-daily nucleotide analog polymerase inhibitor, is indicated for use in combination with ribavirin (RBV) for 12 weeks and the combination is the first all-oral, interferon-free treatment regimen for genotype 2 HCV infection.

The approval is based on data from a Phase III trial conducted in Japan (Study GS-US-334-0118) among treatment-naïve and treatment-experienced genotype 2 patients.

In the trial, 96% of genotype 2 HCV-infected patients received 12 weeks of an all-oral regimen of Sovaldi plus RBV 600-1,000mg/day achieving a sustained virologic response 12 weeks after completing therapy (SVR12).

Gilead Research and Development executive vice-president and chief scientific officer Norbert Bischofberger said: "There is a need in Japan for new HCV treatment options that are more effective and better tolerated and we have been pleased to partner with the medical community here in Japan to demonstrate the efficacy and safety of Sovaldi.

"We look forward to making Sovaldi available in Japan as quickly as possible, while simultaneously continuing to work with the agency on its review of our second application for an all-oral sofosbuvir-based regimen for the treatment of genotype 1 HCV infection."

The Japanese approval is also supported by SVR12 results from four international Phase III trials FISSION, FUSION, POSITRON and VALENCE, which included genotype 2 HCV patients.

The company said that patients who achieve SVR12 are considered cured of HCV infection.

In September 2014, the company filed a new drug application (NDA) in Japan for a single-tablet regimen of sofosbuvir and the NS5A inhibitor ledipasvir to treat genotype 1 HCV infected patients.








1047   Gene therapy using HIV helps children with fatal diseases, study says  이성욱 2013/07/16 2018
1046   Gene therapy 'could be used to treat blindness'Pallab Ghosh  이성욱 2014/01/23 1748
1045   Gene therapy 'hope' on impotence  이성욱 2007/06/04 5004
1044   Gene-therapy hope for β-thalassaemia patients  이성욱 2010/09/21 2483
1043   Genetic circuit kills cancer cells using unique microRNAs  이성욱 2011/09/08 4931
1042   Genetic variant linked to development of liver cancer in hepatitis C virus carriers  이성욱 2011/12/03 2622
1041   Genetically Altered Stem Cells Generate Engineered Cartilage  이성욱 2014/02/22 2057
1040   Genetically Engineered Pigs May Fly as Cancer Models  이성욱 2016/05/17 936
1039   Genetically Modified Stem Cells May Have Therapeutic Application to X-SCID  이성욱 2007/06/04 4478
1038   Genetically 'edited' fruit could soon hit supermarket shelves  이성욱 2014/08/15 1331
1037   Genomics: The single life  이성욱 2012/11/06 2088
1036   Genzyme, Voyager Launch Up-to-$845M Gene Therapy Collaboration  이성욱 2015/02/14 1277
1035   Giant viruses open Pandora's box  이성욱 2013/07/26 2026
1034   Giants of Circadian Biology Win Nobel Prize  이성욱 2017/10/03 519
1033   Gilead Drug Combination Cures Hepatitis C in HIV Patients  이성욱 2014/07/22 1654
1032   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1075
1031   Gilead Licenses Hepatitis Therapy in India Amid Price Criticism  이성욱 2014/09/17 1710
  Gilead secures approval in Japan for Sovaldi to treat genotype 2 chronic HCV  이성욱 2015/03/31 987
1029   Gilead seeks FDA OK for game-changing hepatitis C drug  이성욱 2013/04/10 2115
1028   Gilead submits fixed-dose combination ledipasvir/sofosbuvir HCV tablet for FDA approval  이성욱 2014/02/12 2345

[이전 10개] [1]..[11] 12 [13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN